Home » Stocks » ALEC

Alector, Inc. (ALEC)

Stock Price: $16.38 USD -1.06 (-6.08%)
Updated Jan 21, 2021 12:14 PM EST - Market open
Market Cap 1.38B
Revenue (ttm) 22.25M
Net Income (ttm) -168.58M
Shares Out 78.77M
EPS (ttm) -2.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $16.38
Previous Close $17.44
Change ($) -1.06
Change (%) -6.08%
Day's Open 17.18
Day's Range 16.21 - 17.69
Day's Volume 216,235
52-Week Range 9.40 - 35.28

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 20 hours ago

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that chief busi...

GlobeNewsWire - 1 week ago

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today provided a preview of its...

Seeking Alpha - 3 weeks ago

Alector is a leader in neuroimmunology drug development. This has enabled the company to build a pipeline of medicines pursuing large and important markets from dementia and Alzheimer's.

Seeking Alpha - 1 month ago

Alector, Inc (Nasdaq: ALEC) is a clinical-stage biopharmaceutical company focused on immuno-neurology, immune dysfunction studies related to degenerative brain disorders. Alector has 4-clinica...

Other stocks mentioned: ABBV
GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney...

Zacks Investment Research - 2 months ago

Alector (ALEC) delivered earnings and revenue surprises of -24.07% and -22.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate updat...

Zacks Investment Research - 2 months ago

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that an indepen...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of...

Zacks Investment Research - 3 months ago

Alector (ALEC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members...

InvestorPlace - 5 months ago

Baby boomers have a reputation of being old and therefore irrelevant. However, this powerful and influential generation can spark huge demand for many stocks to buy.

Other stocks mentioned: AIG, AMP, LVS, RCL, SCI, UAL, WELL, Z, ZG
Zacks Investment Research - 5 months ago

Alector (ALEC) delivered earnings and revenue surprises of -11.54% and -64.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced corporate upd...

Seeking Alpha - 5 months ago

Alector Looks Like A Buy After Huge Selloff

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah On...

The Motley Fool - 5 months ago

Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced preliminary d...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced dosing of the...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the comp...

Zacks Investment Research - 8 months ago

Alector (ALEC) delivered earnings and revenue surprises of -10.42% and -32.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical- stage biotechnology company pioneering immuno-neurology, today announced business high...

Zacks Investment Research - 9 months ago

Is (ALEC) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 9 months ago

SOUTH SAN FRANCISCO, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company and leader in the discovery and development of therapeuti...

Zacks Investment Research - 9 months ago

Alector (ALEC) delivered earnings and revenue surprises of -2.27% and -37.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 9 months ago

SOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) today announced the addition of Paula Hammond, Ph.D., to the Company’s Board of Directors. Dr. Ha...

Zacks Investment Research - 10 months ago

Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 10 months ago

Alector (ALEC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 10 months ago

Investors need to pay close attention to Alector (ALEC) stock based on the movements in the options market lately.

Zacks Investment Research - 10 months ago

Alector (ALEC) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the U.S....

GlobeNewsWire - 11 months ago

- Total gross proceeds from the offering to Alector are approximately $240 million - Total gross proceeds from the offering to Alector are approximately $240 million

GlobeNewsWire - 11 months ago

Total gross proceeds from the offering to Alector, including from the sale of the additional shares, are expected to be approximately $240 million Total gross proceeds from the offering to Ale...

GlobeNewsWire - 11 months ago

Public Offering of 8,350,000 Shares of Common Stock for Gross Proceeds of Approximately $208 Million Public Offering of 8,350,000 Shares of Common Stock for Gross Proceeds of Approximately $20...

Seeking Alpha - 11 months ago

Alector: A Promising Neuro-Immunology Pick For 2020

GlobeNewsWire - 11 months ago

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it intends to...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that in Decem...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Alector Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it has be...

Benzinga - 1 year ago

Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.

Other stocks mentioned: AMGN, FULC, RARE, RDUS, SAGE, SRPT, VRTX
GlobeNewsWire - 1 year ago

During its R&D day, company announced that Drs. Scheller and Südhof will support its mission to pioneer the discovery and development of transformative immune therapies for neurodegeneration D...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointme...

The Motley Fool - 1 year ago

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Other stocks mentioned: AGN, AMRN, ATNX, BHVN, CARA, GBT, ITCI, NVS, PBYI, PTGX, PTI, RCKT
GlobeNewsWire - 1 year ago

- Today’s AL002 presentation showcases the first data in humans with a TREM2 antibody

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that the U.S....

24/7 Wall Street - 1 year ago

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval.

Other stocks mentioned: ACAD, AMRN, AVDL, BHC, BIIB, EPZM, GTHX, MGNX, SYRS
The Motley Fool - 1 year ago

No new drugs have been approved for Alzheimer’s disease since 2003. However, new approaches may soon bring options for the 5.7 million Americans suffering from the disease.

Other stocks mentioned: DNLI

About ALEC

Alector, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In ad... [Read more...]

Industry
Biotechnology
IPO Date
Feb 7, 2019
CEO
Arnon Rosenthal
Employees
162
Stock Exchange
NASDAQ
Ticker Symbol
ALEC
Full Company Profile

Financial Performance

In 2019, Alector's revenue was $21.22 million, a decrease of -23.33% compared to the previous year's $27.68 million. Losses were -$105.39 million, 101.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Alector stock is "Strong Buy." The 12-month stock price forecast is 32.13, which is an increase of 96.15% from the latest price.

Price Target
$32.13
(96.15% upside)
Analyst Consensus: Strong Buy